Is the Daiichi Sankyo Co Dividend Safe?
Daiichi Sankyo Co has been increasing the dividend for 4 years.
Over the past 10 years, Daiichi Sankyo Co has increased it by an annual 11.612 %.
Over a five-year period, the distribution increased by 20.791%.
Analysts expect a Dividend Increase of 0.694% for the current fiscal year.
Daiichi Sankyo Co Aktienanalyse
What does Daiichi Sankyo Co do?
Daiichi Sankyo Co Ltd is a company specialized in the production of medicines. The company was founded in 2005 and was formed from the merger of two Japanese pharmaceutical companies.
However, the history of Daiichi Sankyo dates back to 1899 when the Daiichi Group and Sankyo Renkyu merged to form a cooperative. Both companies had been active in the pharmaceutical business since the 1960s and were specialized in the development and production of drugs.
Daiichi Sankyo's business model is focused on developing and globally marketing innovative drugs. The company focuses on researching and marketing drugs for the treatment of cancer, cardiovascular diseases, and infectious diseases.
Daiichi Sankyo is divided into different divisions. The pharmaceutical division is the company's most important business segment. Here, drugs for various applications are developed and produced, including medications for the therapy of cancer, cardiovascular diseases, and infections.
Another division is the medical devices division. Here, medical devices such as catheters and stents for the treatment of cardiovascular diseases, as well as endoscopic devices for the diagnosis and therapy of gastrointestinal diseases, are manufactured.
Another important area is the diagnostics division. Here, diagnostic test systems for various applications are developed and manufactured.
Some of Daiichi Sankyo's best-known products include the cancer drug Trastuzumab Emtansin and the anticoagulant drug Prasugrel.
Daiichi Sankyo is a globally operating company headquartered in Tokyo, Japan. In addition, the company has branches in North, Central, and South America, Europe, Asia, and Oceania.
The company places great importance on research and development and participates in numerous collaborations and partnerships with universities and other companies. The goal is to constantly develop new groundbreaking drugs and contribute to the improvement of disease treatment.
Overall, Daiichi Sankyo employs approximately 15,000 people worldwide and generates an annual revenue of around 8 billion euros. The company is thus one of the leading companies in the pharmaceutical and medical technology industry and will remain an important player in the global healthcare market in the future. Daiichi Sankyo Co is one of the most popular companies on Eulerpool.com.Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Daiichi Sankyo Co stock can be added to a savings plan with the following providers: Consorsbank